Combined therapy with an ACE-inhibitor and a statin, particularly perindopril and atorvastatin, consistently reduces the rate of ASCVD events in patients with hypertension and lipid disorders.
Does combination therapy with ACE inhibitors and statins reduce ASCVD events in patients with hypertension and lipid disorders?
The combination of ACE inhibitors and statins, particularly perindopril and atorvastatin, provides synergistic benefits in reducing ASCVD events in patients with hypertension and hypercholesterolemia.
AIMS: Hypertension and hypercholesterolemia are independent risk factors for atherosclerotic cardiovascular disease (ASCVD) by acting directly on the endothelium and activating the renin-angiotensin aldosterone system (RAAS) and mevalonate pathways. This review examines how the severity and duration of these risk factors may influence the cardiovascular risk through a reciprocal interplay leading to oxidative stress and pro-inflammatory response. DATA SYNTHESIS: The review highlights the clinical evidence supporting the benefits of statins and angiotensin-converting enzyme (ACE) inhibitors for hypertension, lipid disorders and ASCVD management, both individually and combined, at all stages of the cardiovascular continuum. CONCLUSION: Drug strategies incorporating an ACE-inhibitor and a statin, and in particular perindopril and atorvastatin, have consistently demonstrated reductions in the rate of ASCVD events in patients with hypertension and lipid disorders, cementing their position as first-line therapies for the management of atherosclerosis complications.
Borghi et al. (Tue,) conducted a review in Hypertension, hypercholesterolemia, and atherosclerotic cardiovascular disease (ASCVD). ACE inhibitors and statins (specifically perindopril and atorvastatin) was evaluated on ASCVD events. Combined therapy with an ACE-inhibitor and a statin, particularly perindopril and atorvastatin, consistently reduces the rate of ASCVD events in patients with hypertension and lipid disorders.